AstraZeneca's severe asthma drug breezes into phase III trials
- Tralokinumab is a monoclonal antibody that targets interleukin-13.
- This targeted treatment is being tested for patients with severe asthma who have not responded to inhaled corticosteroids and long-acting beta-2 agonists.
- Tralokinumab is also being tested in phase II trials for patients with mild-to-moderate idiopathic pulmonary fibrosis.
Phase III studies of trakolinumab will focus on adolescents and adults. The goal is to determine how this medication affects lung function, patient-reported symptoms, quality of life, and the extent to which it controls asthmatic exacerbation.
One component of the study will also focus on the role of biomarkers in disease pathophysiology. Approval of trakolinumab would provide another much-needed treatment option for asthma, which affects almost 26 million Americans.